Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.
Yanhang GaoFei KongGuangming LiCheng LiSujun ZhengJianmei LinXiaofeng WenJin-Hua HuXiaozhong WangXiaofeng WuHuichun XingJidong JiaZhansheng JiaYujuan GuanChenghao LiGuicheng WuZhiliang GaoZhuangbo MouQin NingQing MaoYongfeng YangJing NingLi LiHai PanDesheng ZhouYanhua DingHong QinJunqi NiuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
The regimen of coblopasvir and sofosbuvir is a safe and effective treatment for Chinese patients with genotype 1, 2, 3 and 6 HCV infection, including those with compensated cirrhosis. Therefore, this regimen would be a novel choice of treatment for this patient population.